Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update

2 years ago

WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive…

Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

2 years ago

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing…

Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

2 years ago

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative…

Avalo Therapeutics Announces Leadership Transition

2 years ago

Promotes Dr. Garry Neil to Chief Executive OfficerPromotes Chris Sullivan to Chief Financial Officer WAYNE, Pa. and ROCKVILLE, Md., Feb.…

XOMA to Present at Aegis Capital Corp Investor Conference

2 years ago

EMERYVILLE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role…

Repligen Reports Fourth Quarter and Full Year 2021 Financial Results

2 years ago

— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72% — Record revenue of $670.5 million…

Ultimovacs ASA: Mandatory notification of trade by primary insider

2 years ago

Oslo, 17 February 2022, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000…

Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

2 years ago

CALGARY, Alberta, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that the first Brazilian site has…

Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions

2 years ago

TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"),…

Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis

2 years ago

CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines…